OMAHA, Nebraska (December 11, 2018)—The final results are in, and the inaugural MidWest Drug Development Conference was an unqualified success, UNeMed announced today.
“No question about it,” said Michael Dixon, CEO and President at UNeMed, the event’s primary host. “Taking a swing at something major like this is more than a little nerve-wracking. Will anyone show up? Are we wasting our time? But this was a home run, no doubt—and not just for us.”
As the first-ever Midwest Drug Development Conference winds down, please take a moment to help us learn where we went wrong, where we went right and how to improve the event for next year, or even if the event is worth repeating. It’s only 10 questions and should only take about four minutes.
It’s last call for presentations at the Midwest Drug Development conference, officials announced today.
Only 10 slots remain open in the two-day slate of early- and mid-stage technologies that will be presented to guests from the worlds of biomedical therapeutics and investor groups.
The MidWest Drug Development Conference is now accepting registrations to attend a two-day event focused on highlighting the best early- and mid-stage therapeutic technologies that Midwestern universities have to offer.
The Midwest Drug Development Conference, a new biomedical partnering event, will come to Omaha next year, officials at the University of Nebraska Medical Center and its technology transfer and commercialization office, UNeMed, announced today.
